201012-1335嗯嗯呃(6)

嗯嗯呃

- 6 - 中国科技论文在线Tab. 3 Effect of trans-tiliroside on TG, TC in normal and alloxan-induced diabetic mice

Group Treatment (mg/kg/p.o.) TC （mmol/L ） TG （mmol/L ）

I Normal control 2.51±0.52** 0.77±0.42**

Ⅱ Normal+trans-tiliroside (0.4) 2.35±0.50** 0.96±0.53**

Ⅲ Diabetic control 6.38±2.69## 2.53±2.16##

Ⅳ Diabetic+trans-tiliroside (0.4) 3.37±0.83** 1.37±0.66*

Ⅴ Diabetic+trans-tiliroside (0.8) 3.28±0.93** 1.20±1.08**

Ⅵ Diabetic+trans-tiliroside (1.6) 3.14±0.28** 1.16±0.59** Ⅶ Metformin control (125) 4.28±1.22**## 1.04±0.52**

Values are expressed as mean ±S.E.M.of ten observations. * p <0.05 compared with diabetic control group. ** p <0.01 compared with diabetic control group. ##p <0.01 compared with normal control group.

Tab. 4 Effects of trans-tiliroside on blood lipid in normal and STZ-induced diabetic rats

Group Treatment (mg/kg/p.o.) TC （mmol/L ）TG （mmol/L ）HDL-C （mmol/L ） LDL-C （mmol/L ）I Normal control 2.02±0.57** 1.36±0.48** 0.98±0.19** 0.26±0.07**

Ⅱ Normal+trans-tiliroside (1.2) 1.93±0.29** 1.13±0.45** 1.01±0.16** 0.24±0.06**

Ⅲ Diabetic control 7.31±1.14## 2.92±1.05## 0.63±0.31## 0.83±0.50##

Ⅳ

Diabetic+trans-tiliroside (0.3) 5.45±1.98*##★ 1.50±0.79** 0.88±0.16*☆ 0.55±0.22*## Ⅴ

Diabetic+trans-tiliroside (1.2) 4.36±0.71**## 1.30±0.48** 0.92±0.21**☆☆ 0.42±0.15** Ⅵ Metformin control (93.75) 4.97±1.89*## 1.58±0.69** 0.64±0.17△ 0.55±0.24*##

Values are expressed as mean ±S.E.M.of eight observations.

* p <0.05 compared with diabetic control group. ** p <0.01 compared with diabetic control group.

##p <0.01 compared with normal control group. ☆p <0.05, ☆☆p <0.01 compared with metformin control group.

★p <0.05 compared with diabetic+trans-tiliroside (1.2 mg/kg) group.

2.5 Measurement of SOD and MDA level in normal and STZ-induced diabetic rats

Table 5 shows the MDA level and SOD activities level in normal and STZ-induced diabetic rats. MDA was significantly increased whereas SOD activities were significantly decreased in diabetic rats compared to normal rats. All these changes enhanced oxidative stress condition, which was counteracted by the tested compound. Trans-tiliroside (0.3 and 1.2 mg/kg) caused significantly decreased in MDA and was associated with a marked increase SOD activities in serum compared to STZ-induced diabetic rats. The trans-tiliroside did not have any marked change on all these oxidative stress markers in normal rats.

Tab. 5 Effect of trans-tiliroside on MDA level and SOD activities in in normal and STZ-induced diabetic rats Group Treatment (mg/kg/p.o.) SOD (U/ml) MDA (nmol/ml)

Ⅱ Normal+trans-tiliroside (1.2) 60.36±11.89** 4.64±0.78**

Ⅲ Diabetic control 18.62±13.18## 7.13±1.08##

Ⅳ Diabetic+trans-tiliroside (1.2) 40.90±11.32**## 5.72±1.33**##

Ⅴ Diabetic+trans-tiliroside (0.3) 32.64±15.56*## 6.01±1.10*## Ⅵ Metformin control (93.75) 24.87±20.57## 5.92±1.26*##

Values are expressed as mean ±S.E.M.of eight observations. * p <0.05 compared with diabetic control

group.

** p <0.01 compared with diabetic control group. ##p <0.01 compared with normal control group. 2.6 Histopathological examination

Histopathological changes of pancreas are given in Fig.3. Based on H&E stained tissue sections, normal control rats showed no notable changes in pancreas histology throughout the 12 weeks study (Fig.3A). In contrast, STZ administration elicited severe injury of pancreas, such as decreasing of the islet cells’ numbers and diminishing of the diameter of pancreatic island. The islets were shrunken in diabetic rats when compared with normal rats (Fig. 3B). Administration with the trans-tiliroside (1.2 and 0.3 mg/kg) and metformin (93.75 mg/kg) showed moderate